PMID- 24776735
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20220317
IS  - 1423-0194 (Electronic)
IS  - 0028-3835 (Linking)
VI  - 99
IP  - 2
DP  - 2014
TI  - Predictive value of gastrin levels for the diagnosis of gastric 
      enterochromaffin-like cell hyperplasia in patients with Hashimoto's thyroiditis.
PG  - 118-22
LID - 10.1159/000362879 [doi]
AB  - AIM: Gastrin and chromogranin A (CgA) levels have been tested for the diagnosis 
      of enterochromaffin-like cell hyperplasia (ECLH) in patients with type 1 diabetes 
      and autoimmune atrophic gastritis but not for patients with Hashimoto's 
      thyroiditis (HT). The aim of the study was to develop receiver operating 
      characteristic (ROC) curves for gastrin and CgA levels and other clinical and 
      biochemical parameters, as means for pretest probability of gastric ECLH in 
      patients with HT. METHODS: A total of 115 patients with HT were prospectively 
      studied for a median period of 4 (2-7) years. Gastrin, CgA, vitamin B12, 
      anti-parietal cell antibodies, free thyroxine, thyrotropin, and neuron-specific 
      enolase levels were measured. Their predictive values were calculated according 
      to the histological findings for ECLH diagnosis from 
      esophagogastroduodenoscopy-obtained biopsies. RESULTS: Thirteen patients (11.3%) 
      had ECLH. The areas under the curve for gastrin and CgA level were 0.898 (p < 
      0.001) and 0.853 (p < 0.001), respectively. The product sensitivity x specificity 
      was 0.803 and 0.653 for gastrin and CgA levels >89.5 and >89.1 ng/ml, 
      respectively. Two and 4 patients with ECLH had normal gastrin and CgA levels, 
      respectively. The most specific combined parameters predicting ECLH were gastrin 
      >89.5 ng/ml with concomitant low B12 levels (96.1% specificity). CONCLUSION: 
      Gastrin levels have high diagnostic accuracy for ECLH identification in patients 
      with HT, and are highly specific when combined with low B12 levels. However, they 
      should be interpreted with caution, as some patients may harbor gastric ECLH even 
      if gastrin levels are not increased, necessitating further follow-up.
CI  - (c) 2014 S. Karger AG, Basel
FAU - Nicolaou, Argyro
AU  - Nicolaou A
AD  - Endocrine Unit, Department of Pathophysiology, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Thomas, Dimitrios
AU  - Thomas D
FAU - Alexandraki, Krystallenia I
AU  - Alexandraki KI
FAU - Sougioultzis, Stavros
AU  - Sougioultzis S
FAU - Tsolakis, Apostolos V
AU  - Tsolakis AV
FAU - Kaltsas, Gregory
AU  - Kaltsas G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20140424
PL  - Switzerland
TA  - Neuroendocrinology
JT  - Neuroendocrinology
JID - 0035665
RN  - 0 (Biomarkers)
RN  - 0 (Chromogranin A)
RN  - 0 (Gastrins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Chromogranin A/*blood
MH  - Diabetes Mellitus, Type 1/complications
MH  - Enterochromaffin-like Cells/*pathology
MH  - Female
MH  - Gastrins/*blood
MH  - Hashimoto Disease/*complications
MH  - Humans
MH  - Hyperplasia/blood/diagnosis/pathology
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - ROC Curve
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Stomach/*pathology
MH  - Stomach Diseases/*diagnosis/epidemiology/*pathology
EDAT- 2014/04/30 06:00
MHDA- 2015/07/21 06:00
CRDT- 2014/04/30 06:00
PHST- 2014/01/29 00:00 [received]
PHST- 2014/04/12 00:00 [accepted]
PHST- 2014/04/30 06:00 [entrez]
PHST- 2014/04/30 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
AID - 000362879 [pii]
AID - 10.1159/000362879 [doi]
PST - ppublish
SO  - Neuroendocrinology. 2014;99(2):118-22. doi: 10.1159/000362879. Epub 2014 Apr 24.